Hormone-Resistant Metastatic Prostate Cancer
| Autor: | Sakari Rannikko, Inkeri Elomaa, Pirkko Kellokumpu-Lehtinen, O. Alfthan |
|---|---|
| Rok vydání: | 1991 |
| Předmět: |
medicine.medical_specialty
Urology medicine.medical_treatment 030232 urology & nephrology law.invention 03 medical and health sciences Prostate cancer 0302 clinical medicine Randomized controlled trial Refractory law Prostate medicine Chemotherapy business.industry medicine.disease 3. Good health Surgery medicine.anatomical_structure 030220 oncology & carcinogenesis Toxicity Estramustine business medicine.drug Epirubicin |
| Zdroj: | European Urology. 19:12-15 |
| ISSN: | 1873-7560 0302-2838 |
| DOI: | 10.1159/000473570 |
| Popis: | We compared the effect and toxicity of estramustine phosphate and weekly low-dose epirubicin in a prospective randomized trial in 41 patients with metastatic prostate cancer refractory to hormonal manipulation. No significant difference between treatment modalities was seen. Palliation was reached in over 60% of patients. The median survival was 15 months in both groups. Toxicity was mild. Further, we investigated the effect of epirubicin after the failure of preceding estramustine phosphate therapy in additional 20 patients. Pain relief was achieved in 50% of these patients. The median survival was 10 months. Toxicity was acceptable. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|